Evidence map›Paper›PMID 34981490›Full record

Trial reportAdvances in experimental medicine and biology2021

Safety and Efficacy of Oral Supplementation of Lentil (Lens culinaris Medic) in Dry Eye Patients.

Yunes Panahi, Mehdi Roozbahani, Shiva Pirhadi, Hossein Aghamollaei, Farhad Nejat, Mostafa Naderi, Sara Serahati, Khosrow Jadidi, Thozhukat Sathyapalan, Tannaz Jamialahmadi and 1 more

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Advances in experimental medicine and biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yunes PanahiPharmacotherapy Department, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Mehdi RoozbahaniDepartment of Ophthalmology, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Shiva PirhadiDepartment of Biomedical Engineering, Science and Research Branch, Islamic Azad University, Tehran, Iran.
Hossein AghamollaeiApplied Biotechnology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Farhad NejatVision Health Research Center, Tehran, Iran.
Mostafa NaderiDepartment of Ophthalmology, Chemical Injuries Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Sara SerahatiSchool of Public Health, University of Saskatchewan, Saskatoon, Canada.
Khosrow JadidiDepartment of Ophthalmology, Baqiyatallah University of Medical Sciences, Tehran, Iran. kh.jadidi@gmail.com.
Thozhukat SathyapalanAcademic Diabetes, Endocrinology and Metabolism, Hull York Medical School, University of Hull, Hull, UK.
Tannaz JamialahmadiDepartment of Food Science and Technology, Quchan Branch, Islamic Azad University, Quchan, Iran.
Amirhossein SahebkarBiotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran. sahebkara@mums.ac.ir.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo evaluate the safety and efficacy of dietary lentil capsules in patients suffering from dry eye symptoms.

methodsA randomized, triple-blind, interventional, placebo-controlled study was done. Sixty patients were randomized in two groups to receive either one capsule containing 500 mg of lentil powder or placebo daily for 3 months. UCVA, tear film breakup time (TBUT), Schirmer's test, tear film osmolarity, and OSDI score were recorded at baseline and 3 months after intervention. Data analysis was performed using IBM SPSS for Windows version 20 (SPSS, Chicago, IL, USA).

resultsIn the lentil group, at baseline, the mean UCVA (LogMAR), OSDI, TBUT (S), tear film osmolarity (mOsm/L), and Schirmer (mm) scores were 0.104 (0.026), 22.66 (19.40), 10.31 (5.32), 301.07 (15.57), and 8.22 (6.87), respectively. These values were 0.101 (0.026), 20.85 (19.44), 13.04 (7.11), 299.81 (11.60), and 9.87 (10.11). In the placebo group, these values were 0.084 (0.027), 25.35 (20.08), 10.56 (4.95), 299.77 (15.09), and 9.35 (8.06) at baseline and 3 months later were 0.077 (0.027), 23.32 (22.90), 13.62 (6.30), 297.54 (12.08), and 8.64 (9.60), respectively. Three patients (one in the lentil group and two in the placebo group) experienced severe gastrointestinal symptoms.

conclusionAlthough consumption of 500 mg of lentil is safe, this amount is not sufficient for reduction of dry eye syndrome in 3 months. For more validation, a clinical study with increased dosage of lentil is proposed.

Indexed as

Dry Eye SyndromesLens PlantDietary SupplementsHumansOsmolar ConcentrationPlant PreparationsTearsPlant PreparationsDry eye diseaseLentilRandomized controlled trial

Identifiers

PMID34981490

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.